FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered undruggable. The company's cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP's to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention.
We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines.